BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14987278)

  • 1. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA.
    Valkova S; Trashlieva M; Christova P
    Clin Exp Dermatol; 2004 Mar; 29(2):180-4. PubMed ID: 14987278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results in the treatment of vitiligo with oral khellin plus UVA.
    Hofer A; Kerl H; Wolf P
    Eur J Dermatol; 2001; 11(3):225-9. PubMed ID: 11358729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro.
    Carlie G; Ntusi NB; Hulley PA; Kidson SH
    Br J Dermatol; 2003 Oct; 149(4):707-17. PubMed ID: 14616361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study.
    Ermis O; Alpsoy E; Cetin L; Yilmaz E
    Br J Dermatol; 2001 Sep; 145(3):472-5. PubMed ID: 11531839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of vitiligo with khellin and ultraviolet A.
    Ortel B; Tanew A; Hönigsmann H
    J Am Acad Dermatol; 1988 Apr; 18(4 Pt 1):693-701. PubMed ID: 3270995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case study to evaluate the treatment of vitiligo with khellin encapsulated in L-phenylalanin stabilized phosphatidylcholine liposomes in combination with ultraviolet light therapy.
    de Leeuw J; van der Beek N; Maierhofer G; Neugebauer WD
    Eur J Dermatol; 2003; 13(5):474-7. PubMed ID: 14693493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provocation of porphyria cutanea tarda by KUVA-therapy of vitiligo.
    Jansen T; Megahed M; Hölzle E; Plewig G
    Acta Derm Venereol; 1995 May; 75(3):232-3. PubMed ID: 7653185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadband ultraviolet A vs. psoralen ultraviolet A in the treatment of vitiligo: a randomized controlled trial.
    El Mofty M; Bosseila M; Mashaly HM; Gawdat H; Makaly H
    Clin Exp Dermatol; 2013 Dec; 38(8):830-5. PubMed ID: 23551324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An objective assessment of melanin in vitiligo skin treated with Balneo PUVA therapy.
    Hegyi V; Petrovajová M; Novotný M
    Skin Res Technol; 2014 Feb; 20(1):108-15. PubMed ID: 23800185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the combination of calcipotriol and PUVA effective in vitiligo?
    Baysal V; Yildirim M; Erel A; Kesici D
    J Eur Acad Dermatol Venereol; 2003 May; 17(3):299-302. PubMed ID: 12702070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study.
    Yalçin B; Sahin S; Bükülmez G; Karaduman A; Atakan N; Akan T; Kölemen F
    J Am Acad Dermatol; 2001 Apr; 44(4):634-7. PubMed ID: 11260538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Childhood vitiligo successfully treated with bath PUVA.
    Mai DW; Omohundro C; Dijkstra JW; Bailin PL
    Pediatr Dermatol; 1998; 15(1):53-5. PubMed ID: 9496807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitiligo treatment.
    Ortel B; Tanew A; Hönigsmann H
    Curr Probl Dermatol; 1986; 15():265-71. PubMed ID: 3948525
    [No Abstract]   [Full Text] [Related]  

  • 14. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study.
    Kwok YK; Anstey AV; Hawk JL
    Clin Exp Dermatol; 2002 Mar; 27(2):104-10. PubMed ID: 11952699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An approach to the treatment of vitiligo by khellin.
    Abdel-Fattah A; Aboul-Enein MN; Wassel GM; El-Menshawi BS
    Dermatologica; 1982 Aug; 165(2):136-40. PubMed ID: 6754485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches.
    Parsad D; Pandhi R; Dogra S; Kumar B
    J Am Acad Dermatol; 2004 Jan; 50(1):63-7. PubMed ID: 14699367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of vitiligo with khellin liposomes, ultraviolet light and blister roof transplantation.
    de Leeuw J; Assen YJ; van der Beek N; Bjerring P; Martino Neumann HA
    J Eur Acad Dermatol Venereol; 2011 Jan; 25(1):74-81. PubMed ID: 20477914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study.
    Sapam R; Agrawal S; Dhali TK
    Int J Dermatol; 2012 Sep; 51(9):1107-15. PubMed ID: 22909369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PUVA treatment of vitiligo: a retrospective study of Turkish patients.
    Sahin S; Hindioğlu U; Karaduman A
    Int J Dermatol; 1999 Jul; 38(7):542-5. PubMed ID: 10440288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study.
    Bhatnagar A; Kanwar AJ; Parsad D; De D
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1381-5. PubMed ID: 17958845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.